Phase I/II clinical trial of vorinostat in patients with recurrent and/or metastatic breast cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2013
At a glance
- Drugs Vorinostat (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 09 Dec 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 25 Mar 2012 Planned end date (Jan 2013) added as reported by ClinicalTrials.gov.